Story perspectives

Appeals Court Revives Whistleblower Suit Against Major Drug Companies

3/19/2026

Summary

Story summary

A U.S. appeals court reinstated a whistleblower suit against AbbVie, AstraZeneca, Novartis, and Sanofi for alleged overcharges under the Section 340B Drug Pricing Program.
The ruling allows the claims to proceed, potentially costing governments hundreds of millions.
The suit, brought by Adventist Health System/West, alleges violations of the federal False Claims Act for pricing noncompliance.
The case returns to U.S. District Judge Dale Fischer for further proceedings after a dismissal.

History

Historical Context

The False Claims Act, originally enacted in 1863 during the Civil War to combat fraud against the Union Army, was significantly amended in 1986 to strengthen protections for whistleblowers. This law has since recovered over $60 billion, particularly impacting the healthcare sector. The recent whistleblower suit against AbbVie, AstraZeneca, Novartis, and Sanofi underscores ongoing compliance challenges in drug pricing practices.

1 of 2

Story summary

A U.S. appeals court reinstated a whistleblower suit against AbbVie, AstraZeneca, Novartis, and Sanofi for alleged overcharges under the Section 340B Drug Pricing Program.
The ruling allows the claims to proceed, potentially costing governments hundreds of millions.
The suit, brought by Adventist Health System/West, alleges violations of the federal False Claims Act for pricing noncompliance.
The case returns to U.S. District Judge Dale Fischer for further proceedings after a dismissal.

1 / 2